creation date: 2025-06-30 13:56
tags: Pathologies

Acute Exacerbation of COPD

Background

Definitions

Exacerbation of chronic obstructive pulmonary disorder. This generally includes an acute change or worsening of one or more of the cardinal symptoms:

Increased frequency and severity of cough
Sputum production increases in volume
Dyspnea increases

Etiology and Pathogenesis

There are several potential triggers of exacerbation:

Viral or bacterial infection (70% of cases)
Environmental pollution
Weather conditions
Pulmonary embolism
Other medical conditions

Risk factors

A number of features increase the risk of developing an exacerbation:

Advanced age
Productive cough
Longer duration of COPD
History of antibiotic therapy
COPD-related hospitalization in previous year
Chronic mucous hypersecretion and mucus plugs
Peripheral blood eosinophil >0.34 $\times 1 0^{9}$ cells/L
Theophylline therapy
Use of medication that causes sedation or respiratory depression (eg. opioids, benzodiazepines)
Presence of comorbidities (eg. heart failure)
History of GERD, LV diastolic dysfunction, and/or pulmonary hypertension

Clinical Presentation

Signs & Symptoms

Manifestation of AECOPD can range from mild increase in symptoms to respiratory failure and/or hypoxemia.

By definition, acute onset or worsening of respiratory symptoms:

Dyspnea
Cough
Sputum production

The worsening usually occurs over several hours to days.

History & Physical Exam

History should elicit:

Time course of symptoms
Comparison to baseline symptoms
Severity of respiratory compromise
Sputum characteristics
Use of home oxygen
Symptoms that may suggest other etiology including constitutional symptoms, chest pain, palpitations, peripheral edema
Upper respiratory symptoms that might suggest trigger
Risk factor for coronary disease or thromboembolic disease

Physical exam may find associated findings to symptoms:

Wheezing
Tachypnea
Use of accessory respiratory muscles
Paradoxical chest wall/abdominal movements
Tachycardia

Diagnosis

Criteria

AECOPD is diagnosed clinically by presence of two of the following three ≤14 days:

Increased cough
Increased sputum production
Increased dyspnea

Severity is described as:

Mild:

Dyspnea <5 on visual analog scale (1-10)
Respiratory rate <24 breaths/min
Heart rate <95 bpm
Resting SaO2 ≥92% in ambient air or usual oxygen and saturation ≤3% from baseline
CRP <10 mg/L
Moderate (at least 3 of the following)
Dyspnea ≥5 on visual analog scale (1-10)
Respiratory rate ≥24 breaths/min
Heart rate ≥95 bpm
Resting SaO2 <92% in ambient air or usual oxygen and/or saturation ≤3% from baseline
CRP ≥10 mg/L
Severe
Moderate criteria and
Hypercapnia and acidosis on ABG (PaCO2 >45 mmHg and pH <7.35)

Work-up

Initial evaluation depends on severity. In mild cases, clinical assessment may be adequate.

In the context of emergency care, evaluation routinely includes:

Assess pulse oxygen saturation
Chest radiograph to rule out alternative respiratory etiologies
Blood work (eg. CBC, electrolytes, glucose)
ECG for arrhythmias and MI
Arterial blood gas if respiratory acidosis is suspected or if ventilatory support is anticipated

Additional tests can be done to exclude differential diagnoses. The decision to order these tests depend on the degree of uncertainty.

Cardiac evaluation - troponin and NT-proBNP can be used to assess for potential MI and heart failure
CT pulmonary angiogram - for exclusion of pulmonary embolism
Sputum culture - if suspected bacterial infection but initial antibiotic therapy is inadequate
Respiratory viral testing - if antiviral therapy considered

Differential

Patients with acute worsening of dyspnea can be presenting with a number of diagnoses. Among them, the most concerning are:

Heart failure
Cardiac arrhythmias
Pneumonia
Pneumothorax
Pulmonary embolism

Red Flags / Complications

Complications are related to severe exacerbation and possible respiratory failure.

Management

Management is based on severity as described above.

Outpatient

In mild cases without comorbidities, COPD exacerbations can be managed in an outpatient setting.

Initial treatment consist of short-acting inhaled bronchodilators. SABAs are preferred although SABA-SAMA therapy can be used for patients without LAMA therapy.

In cases of influenza or SARS-CoV-2 infection, antiviral and systemic glucocorticoid should be used.

In cases of moderate to severe cases without life-threatening or indication for ventilatory support, patients can be managed in outpatient setting.

In addition to inhalers, glucocorticoids are prescribed. Oral options are typically used but inhaled glucocorticoids are an alternative option.

Prednisone 40mg daily for 5 days (up to 14 days depending on severity)
Budesonide-formoterol 320-9 mcg one inhalation qid

In patients with ≥2 cardinal exacerbation symptoms (increased dyspnea, increased sputum volume/viscosity, or increased sputum purulence), empiric antibiotics are used.

No risk factors: macrolide or 3rd-gen cephalosporin
Risk factors for poor outcomes: amoxicillin-clavulanate or fluoroquinolone
Risk for Pseudomonas infection: ciprofloxacin

Emergency / Inpatient

In patients in the hospital, initial treatment consist of SABA-SAMA combination therapy. Nebulized therapy is preferred but metered dose inhaler is acceptable as well.

Oxygen therapy is used with a target of 88-92% SpO2.

Systemic glucocorticoids are recommended.

Prednisone 40mg daily for 5 days
IV glucocorticoids can be considered for severe exacerbation with poor response to PO treatment

MD Notes

Table of Contents